Switch to: References

Add citations

You must login to add citations.
  1. Managing the Use and Dissemination of Information about Biomarkers: The Importance of Incentive Structures.Ariel Dora Stern - 2019 - Journal of Law, Medicine and Ethics 47 (3):396-397.
    The use of biomarkers holds great promise for the development of new therapeutics and the acceleration of clinical research. However, biomarkers must be validated — a complex and costly endeavor. Importantly, biomarker validation is meaningfully shaped by economic and policy-driven incentives.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  • Biomarker Validation: Context and Complexities.Lisa M. McShane - 2019 - Journal of Law, Medicine and Ethics 47 (3):388-392.
    Validation of a biomarker-based medical product development tool or clinical test is an evidentiary process that must be tailored to the proposed use. Appropriate data and analyses are needed to demonstrate that the biomarker meets analytical and clinical performance criteria consistent with favorable benefit: risk balance.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  • Cochrane's Linked Data Project: How it Can Advance our Understanding of Surrogate Endpoints.Chris Mavergames, Deirdre Beecher, Lorne A. Becker, A. Last & A. Ali - 2019 - Journal of Law, Medicine and Ethics 47 (3):374-380.
    Cochrane has developed a linked data infrastructure to make the evidence and data from its rich repositories more discoverable to facilitate evidence-based health decision-making. These annotated resources can enhance the study and understanding of biomarkers and surrogate endpoints.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   2 citations